Bookmark and Share
BioAssay: AID 493059

Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: fluorescence-based cell-based cytotoxicity assay using 4',6-diamidino-2-phenylindole (DAPI) to identify compounds that are pro-apoptotic in cancer cells grown in culture

Name: Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: fluorescence-based cell-based cytotoxicity assay using 4',6-diamidino-2-phenylindole (DAPI) to identify compounds that are pro-apoptotic in cancer cells grown in culture. ..more
_
   
 Tested Compounds
 Tested Compounds
All(29)
 
 
Active(3)
 
 
Inactive(26)
 
 
 Tested Substances
 Tested Substances
All(29)
 
 
Active(3)
 
 
Inactive(26)
 
 
 Related BioAssays
 Related BioAssays
AID: 493059
Data Source: The Scripps Research Institute Molecular Screening Center (APOPTOSIS_ACT_DAPI_FLUOR_3X%ACT MCSRUN Round 0)
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
Deposit Date: 2011-01-21
Hold-until Date: 2012-01-19
Modify Date: 2012-01-19

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compounds: 3
Related Experiments
Show more
AIDNameTypeProbeComment
2057Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.Screening depositor-specified cross reference: Primary screen (MCL1 and BIM-BH3 peptide interaction inhibitors in singlicate)
2090Summary of probe development efforts to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.Summary depositor-specified cross reference: Summary (MCL1 and BIM-BH3 peptide interaction inhibitors)
2129Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).Screening depositor-specified cross reference: Primary screen (BCLXL inhibitors in singlicate)
2166Counterscreen for MCL1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of BCL2-related protein, long isoform (BCLXL).Screening depositor-specified cross reference: Counterscreen (BCLXL inhibitors in triplicate)
2168Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.Screening depositor-specified cross reference: Confirmation screen (MCL1 and BIM-BH3 peptide interaction inhibitors in triplicate)
2217Fluorescence polarization-based biochemical high throughput dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.Confirmatory depositor-specified cross reference: Dose response (MCL1 and BIM-BH3 peptide interaction inhibitors in triplicate)
2218Counterscreen for inhibitors of MCL1: fluorescence polarization-based biochemical high throughput dose response assay for inhibitors of BCL2-related protein, long isoform (BCLXL).Confirmatory depositor-specified cross reference: Dose response counterscreen (BCLXL inhibitors in triplicate)
2790Late stage counterscreen results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of BCL2-related protein, long isoform (BCLXL)Confirmatory depositor-specified cross reference: Late stage dose response counterscreen (BCLXL inhibitors in triplicate)
2791Late stage results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptideConfirmatory depositor-specified cross reference: Late stage dose response (MCL1 and BIM-BH3 peptide interaction inhibitors in triplicate)
602164Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: absorbance-based cell-based assay to identify compounds that are preferentially active in causing apoptosis in Mcl-1 primed (2B4/Mcl1) vs. Bcl-2 (2B4/Bcl-2) cell linesConfirmatory depositor-specified cross reference
602165Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide, Round 3Confirmatory depositor-specified cross reference
624393Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide (Probe)Confirmatory1 depositor-specified cross reference
624411Late stage counterscreen results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of BCL2-related protein, long isoform (BCLXL) (Probe)Confirmatory depositor-specified cross reference
493058Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: absorbance-based cell-based assay to identify compounds that are preferentially active in causing apoptosis in MCL-1 primed vs. Bax/Bak deficient DHL10 cellsConfirmatory same project related to Summary assay
493062Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: fluorescence-based cell-based assay to identify compounds that preferentially activate caspase in 2B4/MCL-1 vs. 2B4/BCL-2 cellsOther same project related to Summary assay
493086Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptideConfirmatory same project related to Summary assay
624396Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: fluorescence-based cell-based cytotoxicity assay using 4',6-diamidino-2-phenylindole (DAPI) to identify compounds that are pro-apoptotic in cancer cells grown in culture (Probe)Other1 same project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Michael Cardone, Eutropics
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R43 CA135915-01 Fast Track
Grant Proposal PI: Michael Cardone, Eutropics
External Assay ID: APOPTOSIS_ACT_DAPI_FLUOR_3X%ACT MCSRUN Round 0

Name: Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: fluorescence-based cell-based cytotoxicity assay using 4',6-diamidino-2-phenylindole (DAPI) to identify compounds that are pro-apoptotic in cancer cells grown in culture.

Description:

Cancer initialization and survival depends upon evasion of the programmed cell death (apoptosis) machinery that normally kills an unneeded or rogue cell (1). Although an effective mechanism for anti-cancer chemotherapeutics is apoptosis induction, cancer cells develop resistance to the pro-apoptotic proteins activated by these drugs (2). Multiple myeloma (MM) and chronic lymphoblastic leukemia (CLL) are two well-characterized lymphoid cancers (3). BCL-2 is an oncoprotein activated in these lymphomas, and serves to inhibit apoptosis induced by many cytotoxic compounds. Members of the BCL-2 protein family are regulated by protein-protein interactions, forming homo- and heterodimers (4, 5). One of these proteins, MCL1, is essential for survival of human MM cells (6). MCL1 and other BXL-2 proteins such as BCL-XL share BCL-2's ability to oppose apoptosis, as well as sequence homology in 4 a-helical BCL-2 homology (BH) regions, BH1-BH4 (3). As a result, these proteins are promising targets for studies on tumor initiation, progression and apoptosis resistance. Research showing that MCL1 opposes cell death (7), is highly expressed in hematopoetic stem cells and is regulated by growth factors (8), and that inhibiting BCL-2 protein-protein interactions via the crucial BH3 domain is a valid approach to cancer drug development (2, 9, 10), suggest that targeted therapies for MCL1 are needed. The identification of selective inhibitors of MCL1 will provide useful tools for the study of lymphoid tumorigenesis, and elucidate mechanisms for apoptosis induction in resistant cancers.

References:

1. McConkey, DJ and Zhu, K, Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat, 2008. 11(4-5): p. 164-79.
2. Reed, JC, Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol, 2006. 3(7): p. 388-98.
3. Cory, S and Adams, JM, Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell, 2005. 8(1): p. 5-6.
4. Petros, AM, Olejniczak, ET and Fesik, SW, Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta, 2004. 1644(2-3): p. 83-94.
5. Redzepovic, J, Weinmann, G, Ott, I and Gust, R, Current trends in multiple myeloma management. J Int Med Res, 2008. 36(3): p. 371-86.
6. Derenne, S, Monia, B, Dean, NM, Taylor, JK, Rapp, MJ, Harousseau, JL, Bataille, R and Amiot, M, Antisense strategy shows that MCL1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood, 2002. 100(1): p. 194-9.
7. Kozopas, KM, Yang, T, Buchan, HL, Zhou, P and Craig, RW, MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A, 1993. 90(8): p. 3516-20.
8. Opferman, JT, Iwasaki, H, Ong, CC, Suh, H, Mizuno, S, Akashi, K and Korsmeyer, SJ, Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science, 2005. 307(5712): p. 1101-4.
9. Letai, A, Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest, 2005. 115(10): p. 2648-55.
10. Oltersdorf, T, Elmore, SW, Shoemaker, AR, Armstrong, RC, Augeri, DJ, Belli, BA, Bruncko, M, Deckwerth, TL, Dinges, J, Hajduk, PJ, Joseph, MK, Kitada, S, Korsmeyer, SJ, Kunzer, AR, Letai, A, Li, C, Mitten, MJ, Nettesheim, DG, Ng, S, Nimmer, PM, O'Connor, JM, Oleksijew, A, Petros, AM, Reed, JC, Shen, W, Tahir, SK, Thompson, CB, Tomaselli, KJ, Wang, B, Wendt, MD, Zhang, H, Fesik, SW and Rosenberg, SH, An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005. 435(7042): p. 677-81.

Keywords:

late stage, powders, purchased, synthesized, chemistry, SAR, myeloma cell leukemia sequence 1, MCL, MCL1, MCL-1, Mcl1, cancer, anti-apoptotic protein, chronic lymphocytic leukemia, multiple myeloma, lymphoma, inhibitor, inhibition, fluorescence, DAPI, chromatin, condensation, morphology, mitochondria, membrane potential, cytochrome c, caspase, cleavage, pycnotic, staurosporine, 2B4, 2B4/MCL-1, 2B4/BCL-2, counterscreen, BH3, Noxa, assay provider, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Protocol
Assay Overview:

The purpose of this assay is to identify compounds that activate caspase 3 and 7 resulting in apoptotic nuclear morphology. As activators of apoptosis, the compounds should increase caspase activity due to loss of mitochondrial membrane potential and cytochrome c release. To visualize the percentage of cells in which there is caspase activity treated cells will be fixed with methanol and stained with the DNA binding DAPI (4',6-diamidino-2-phenylindole) and observed using a fluorescence microscope. The DNA bound dye emits at 456 nm when excited by 350 nm light. Caspase-mediated cleavage of nucleosomal proteins cause condensed, pycnotic nuclear morphology that is easily scored. Percentages of apoptotic cells so scored will be compared to positive control samples treated with Staurosporine. As designed, compounds that induce apoptosis will cause an increase in the number of cells exhibiting high dye uptake and the abnormal pycnotic nuclear morphology. Compounds were tested in triplicate at 25 uM.

Protocol Summary:

Cells were routinely cultured in growth media consisting of Dulbecco's Modified Eagle's Media (DMEM) supplemented with 5% FBS and 1% pen-strep antibiotic mix.

Prior to the start of the assay, cell lines tested were plated at 2E5 cells/mL in 24-well plates in 1 mL of growth media per well, in an atmosphere of 5% CO2 and 95% relative humidity, with or without compound in DMSO, or DMSO alone. Cells treated with 10 uM N-benzoyl staurosporine were also analyzed as a positive control. Cells were treated for 48 hours with 25 uM compound diluted directly into the media from a 10 mM stock solution (2.5 uL added). Following treatment, cells were washed and fixed with ethanol and stained with DAPI following standard protocol. DAPI stock was prepared at 3 uM in staining buffer (100 mM Tris, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% Nonidet P-40). The cell suspension was collected from each well and placed in a 1.5 mL Eppendorf tube. The cells were pelleted by centrifugation (700xg, 5 min). The supernatant was discarded and 1 mL of cold ethanol (-20 C) was added to the cell pellets and incubated on ice for 10 min. The cells were pelleted by centrifugation (700 g, 5 min) and the ethanol was discarded. PBS buffer (10 mM Sodium phosphate, pH 7.4, 150 mM NaCl) was added to the fixed cell pellet to rehydrate the cells for 15 min. The cells were pelleted again by centrifugation, and the supernatant discarded. The cells were resuspended in 0.5 mL of 3 uM DAPI solution, and incubated at room temperature for 15 min. The samples were stored at 4 C until analyzed. Stained cells were mounted and visualized using a florescence microscope (excitation 350 nm, emission 470 nm), and scored (minimum of 100 cells examined) for condensed/pycnotic nuclei. The percent apoptosis was expressed relative to cells treated with DMSO only (0%).

The percent apoptosis was calculated as:

% apoptosis = 100 * ( fraction of apoptotic cells observed at 25 uM).

PubChem Activity Outcome and Score:

An Active compound induces > 15% apoptosis of cells after treatment with 25 uM compound (48 hr).

The reported PubChem Activity Score has been normalized to 100% observed apoptosis. Negative % apoptosis values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-15, and for inactive compounds 14-0.

List of Reagents:

2B4/MCL-1 cells (Dr Tony Letai, Dana Farber Cancer Research Center)
2B4/BCL-2 cells (Dr Tony Letai, Dana Farber Cancer Research Center)
2B4/Bax/Bak(-/-)(Dr Tony Letai, Dana Farber Cancer Research Center)
Control: N-Benzoyl Staurosporine (Calbiochem 539648)
RPMI 1640 (GIBCO 11875 or 11835)+ 1% Pen-Streptomycin-Glutamine (GIBCO 10378) +5% FBS (Hyclone SH30396.02, Thermo Scientific)
4', 6 diamidino-2-phenylindole dihydrochloride (DAPI) dye (Invitrogen, D1306)
Comment
This assay was performed by the assay provider. Replicate values and raw data were not provided. This assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. Possible artifacts of this assay can include, but are not limited to: dust or lint and compounds that modulate fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Format: Cell-based
Assay Type: Toxicity
Assay Cell Type: BCL-2; MCL-1
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Apoptosis at 25 uM (25μM**)Normalized percent apoptosis at a compound concentration of 25 micromolar.Float%

** Test Concentration.
Additional Information
Grant Number: 1 R43 CA135915-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: